Escherichia coli M17

Drug Profile

Escherichia coli M17

Alternative Names: E. coli M17; Probactrix

Latest Information Update: 05 Feb 2015

Price : $50

At a glance

  • Originator The BioBalance Corporation
  • Class Irritable bowel syndrome therapies; Probiotics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Coeliac disease; Gastro-oesophageal reflux; Irritable bowel syndrome

Most Recent Events

  • 05 Feb 2015 Discontinued - Phase-II for Irritable bowel syndrome in USA (PO)
  • 05 Feb 2015 Discontinued - Phase III for Gastro-oesophageal reflux in USA (PO)
  • 05 Feb 2015 Discontinued - Clinical-Phase-Unknown for Coeliac disease in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top